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Abstract
Introduction
Sarcomas represent less than 1% of all diagnosed cancers 
and comprise up to 100 different diagnostic categories. Of 
these categories gastrointestinal stromal tumours (GISTs) are 
the most common, with an incidence of approximately 14.5 
per million people per year as stated in the Swedish tumour 
registry, and a range of 10–15 per million per year as stated 
in a recent systematic reviewed published in 2016.1,2 The 
management of metastatic and high-risk surgically resected 
GISTs is focused on the use of imatinib, a tyrosine kinase 
inhibitor, which has also revolutionised the management of 
chronic myeloid leukaemia via the abl pathway.3 It has been 
shown that GISTs do not respond to conventional cytotoxic 
chemotherapy.1
Parkinson’s disease (PD) is a progressive neurodegenerative 
disease that is characterised by a number of motor and 
non-motor features due to dopaminergic neuronal loss.4 
Meta-analyses have shown that PD prevalence is increasing 
worldwide with 1,903 per 100,000 being affected in those 
over 80 years old. In addition, it has been shown that there 
is a geographic variation in prevalence. Prevalence is higher 
in westernised countries, with 1,601 per 100,000 affected 
in North America, Europe and Australia compared to 646 per 
100,000 in Asia.5
PD has the potential to cause signiﬁ cant impact on a patient’s 
function, and pharmacological management is centred on 
dopamine modulation. There are three cardinal features of 
PD: bradykinesia, resting tremor and rigidity. A number of 
rating scales have been developed to objectify PD severity, of 
which the Uniﬁ ed Parkinson’s Disease Rating Scale (UPDRS) 
is the most established.4,6 A revision of the UPDRS by the 
Movement Disorder Society (MDS-UPDRS) was published in 
2008.7 The MDS-UPDRS includes four domains: 1, non-motor 
experiences of daily living; 2, motor experiences of daily 
living; 3, motor examination; and 4, motor complications. 
We utilised patients ranked on both scores and focused on 
the third domain (objective motor neurological examination) 
that we denote as ‘UPDRS 3’ with R = right side, A = axial 
features and L = left side.
When assessing PD medication it can often be difﬁ cult to 
make a comparison between patients owing to a number of 
different types of dopaminergic medication and variations in 
equivalence. A systematic review by Tomlinson et al. provides 
a standard formula that produces a levodopa equivalent daily 
dose (LEDD) expressed in milligrams per day. This allows 
for comparison of dopaminergic medication across patients 
and studies.8 
We describe two male patients with a concurrent diagnosis of 
PD and metastatic GIST managed with imatinib and standard 
therapy for PD. All available UPDRS scores and LEDDs from 
both electronic ﬁ les and paper case notes were collated. 
There is a potential observation that expected deterioration 
in PD may have been slowed by their concurrent management 
with imatinib.
Imatinib, a tyrosine kinase inhibitor, is the mainstay of treatment for 
resected high-risk (adjuvant and metastatic) gastrointestinal stromal 
tumour (GIST) – a rare form of sarcoma. There has been recent research 
into the neuroprotective role and modulation of dopaminergic neurones by 
imatinib through the abl pathway in Parkinson’s disease (PD). We describe 
two patients from a single cancer centre with concurrent diagnoses of PD 
and metastatic GIST receiving imatinib and standard PD management. The cases highlight a 
potential reduction in PD progression using Uni ed Parkinson’s Disease Rating Scale. Further 
research into repurposing of imatinib for PD may provide additional management options for 
this neurodegenerative illness.
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Case one
A 68-year-old male with PD diagnosed in 2009, initially 
presented with shuffling gait and poor writing. In 2015 
the patient had a UPDRS 3 of 13/132 (bradykinesia = 8, 
rigidity = 5). On examination he had decreased blinking, 
slowed left ﬁ nger taps, hand movements and arm rotation, 
bilateral reduced arm swing and slight stooped posture. LEDD 
at that time was 180. He was commenced on imatinib in 
January 2017 for metastatic GIST (gastric primary with liver 
metastasis and a solitary peritoneal nodule), which was 
diagnosed in December 2016 where UPDRS 3 was 11/132 
(R4/44, A2/44, L5/44). The introduction of imatinib led 
to a partial response and symptomatic improvement, with 
reduction in abdominal pain. Currently, as of May 2017, he 
is being managed with 25 mg carbidopa/100 mg levodopa 
one tablet six-times daily – equating to a LEDD of 600. On 
examination at his last clinic appointment he had general 
slowed movements and mild rigidity with the option to reduce 
his Sinemet® dose owing to dyskinesia. Both dopaminergic 
treatment and complete UPDRS 3 scores are displayed 
chronologically in Figure 1.
Case two
A 72-year-old male was diagnosed and started treatment for 
PD (LEDD 180) in 2003, and subsequently underwent a gastric 
resection for a high-risk GIST in 2009. On follow-up imaging 
in 2014 he had multiple liver lesions, which on biopsy were 
shown to be metastatic GISTs. At this point his UPDRS 3 was 
14/132 (R5/44, A4/44, L5/44). Subsequently the patient 
received imatinib, where his UPDRS 3 was 18/132 (R3/44, 
A8/44, L7/44) in November 2014 with LEDD 1,110 for 36 
months leading to stable disease on CT imaging. He reports 
that imatinib has improved his PD and remains well with a WHO 
performance status of 1. UPDRS 3 in June 2017 was 19/132 
(bradykinesia = 13; rigidity = 2; tremor = 4; postural instability 
= 0). Examination showed slightly affected speech, mildly 
reduced facial expression with reduced blinking, bilaterally 
slowed ﬁ nger tapping, hand movements, pronation/supination, 
reduced right-sided toe tapping and arising from chair, reduced 
right arm swing with stooped posture and bilateral tremor. As of 
January 2018, dopaminergic therapy equated to LEDD 1,425. 
Both dopaminergic treatment and complete UPDRS 3 scores 
are displayed chronologically in Figure 2.
Figure 1 Change in Unified 
Parkinson’s Disease Rating 
Scale 3 (UPDRS 3; left axis) 
and levodopa equivalent daily 
dose (LEDD; right axis) with 
time. a = Parkinson’s disease 
diagnosis; b = metastatic 
gastrointestinal stromal tumour 
diagnosis; c = initiation of 
imatinib; d = most recent 
neurology clinic follow up
Figure 2 Change in Unified 
Parkinson’s Disease Rating 
Scale 3 (UPDRS 3; left axis) 
and levodopa equivalent daily 
dose (LEDD; right axis) with 
time. a = Parkinson’s disease 
diagnosis; b = metastatic 
gastrointestinal stromal tumour 
diagnosis; c = initiation of 
imatinib; d = most recent 
neurology clinic follow up
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Discussion
These two cases raise the possibility that imatinib may 
modulate the severity of PD. Both patients report their 
PD symptoms being less troublesome despite receiving 
additional treatment for their comorbid tumours, which is 
unusual considering that most PD patients with intercurrent 
illness report subjective worsening.9 Some corroboration of 
this clinical impression comes from the routinely obtained 
UPDRS 3 scores, which show stability or improvement since 
the introduction of imatinib.
The pathology of PD is well known. This involves the loss 
of dopaminergic neurones in the substantia nigra and 
development of Lewy bodies in multiple other brain regions.10 
It is believed that the majority of cases are caused by interplay 
of genetic and environmental factors.
Mutations in PRKN gene encoding for Parkin, an ubiquitin 
E3 ligase involved in the degradation of misfolded proteins 
and mitochondrial function, is the most common cause of 
autosomal recessive PD.11,12 However, it has recently been 
shown that Parkin may play a role in sporadic PD as it is 
inactivated owing to nitrosative stress (as a result of reactive 
nitrogen species), dopaminergic stress and oxidative stress: 
key pathophysiological processes in sporadic PD.12
A study from 2010 showed that tyrosine kinase c–abl 
phosphorylation of Parkin, which is activated during 
dopaminergic stress as shown in post-mortem studies, 
inhibited Parkin’s ligase and protective function. Therefore, 
c-abl inhibition may be a neuroprotective strategy in the 
management of PD.13 Imatinib, the drug of choice for high-
risk adjuvant (surgically resected) GIST, has activity against a 
number of kinases, but of importance in this context, abl.14,15
It is difﬁ cult to draw deﬁ nite conclusions from two cases 
regarding progression, but we can benchmark our observations 
against an average increase in UPDRS by 1.2 points per year in 
a large cohort study.16 These ﬁ ndings are therefore preliminary, 
but suggest that observational data on a wider scale, including 
other diagnoses in which this drug class is used, would be 
worthwhile. Future work could be carried out with inclusion 
of this cancer centre’s chronic myeloid leukaemia/PD cohort 
to increase sample size and clarify the correlation between 
UPDRS, LEDD and tyrosine kinase therapy.
There are a number of additional limitations that need to 
be considered. One is the use of dopaminergic medicines 
and the frequency at which PD medication is changed. In an 
attempt to standardise this often difﬁ cult area, we used LEDD 
as described above.
The use of UPDRS 3 should objectify patients’ 
symptomatology; however, there is the possibility that 
external factors may have inﬂ uenced clinical examination. 
We used the UPDRS 3 score, which relates to specialist 
neurological examination and not the more subjective UPDRS 
domains, such as patients’ experiences of daily living. One 
can make the assumption that, in particular, the non-motor 
experiences of daily living (UPDRS 1), which include cognitive 
impairment, depressed mood, anxiety and apathy, may be 
inﬂ uenced by the diagnosis of metastatic cancer.6 We used 
all available UPDRS 3 scores from both electronic notes and 
paper case notes since PD diagnosis. The use of UPDRS has 
become more widely used in recent years, which allows for 
more accurate observations compared to those years nearer 
PD diagnosis.
Clinical trials in the USA are now in the recruiting phase 
to assess the impact of another tyrosine kinase inhibitor, 
nilotinib, and it will be interesting to see their results.17 
Conclusion
Although we did not aim to prove the beneﬁ ts of imatinib 
on PD progression, it does provide observational data that 
suggests stability or improvement in PD severity related 
to imatinib therapy. This is consistent with preclinical 
observations.
Several learning points have been identiﬁ ed: 
• Phosphorylation of Parkin has a detrimental effect on 
neuroprotection in PD.
• There is possible modulation of PD using a tyrosine 
kinase inhibitor, which may help stabilise patients’ 
symptomatology.
• Identiﬁ cation of pathways in rarer diseases may allow for 
repurposing of medication across medical specialties. 
Informed consent 
Written informed consent for the paper to be published 
(including images, case history and data) was obtained 
from the patients for publication of this paper, including 
accompanying images.
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